49,54 $
2,91 %vorgestern
NYSE, 1. März, 22:10 Uhr
ISIN
VGG111961055
Symbol
BHVN
Berichte
Sektor
Industrie

Biohaven Pharmaceutical Holding Company Ltd. Aktie News

Neutral
PRNewsWire
3 Tage alt
Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive-compulsive disorder (OCD), migraine, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Also advan...
Positiv
Seeking Alpha
4 Tage alt
Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with a cash runway extended to 20.7 months post-offering, Biohaven shows robust short-term...
Positiv
InvestorPlace
etwa ein Monat alt
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Positiv
InvestorPlace
etwa ein Monat alt
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Neutral
PRNewsWire
etwa 2 Monate alt
Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Plus, rare autoimmune and inflammatory diseases, including myasthenia gravis, cardiomyopathy, spinal musc...
Neutral
PRNewsWire
2 Monate alt
NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
Neutral
PRNewsWire
3 Monate alt
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous system (CNS) adverse effects associated with other anti-seizure medications (ASMs), such as somnolence and cognitive/mood disturbances. In a Phase 1 electroencephalogram (EEG) biomarker study, BHV-70...
Neutral
PRNewsWire
4 Monate alt
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds of $242 million from completed public offering on October 5, 2023 Completed public offering of 11,761,363 Biohaven Ltd. common shares, which included the exercise in full of the underwriters' option to purchase additional shares, at a price to the ...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen